Licensing status

Publication and contact information



Keratinocyte growth factor receptor (KGFR; FGFR2; CD332); tumor protein p63 (TP63; p63)

Cell culture and mouse studies suggest inhibiting FGFR2 could help treat squamous cell carcinoma (SCC). In a newly developed mouse model of chemically induced SCC, p63-mediated induction of FGFR2 signaling was increased in tumors compared with normal skin, and the small molecule FGFR antagonist AZD4547 arrested tumor development and improved progression-free survival (PFS) compared with vehicle. Next steps include the identification of biomarkers to predict response to FGFR2-directed therapy in SCC.

AstraZeneca plc's AZD4547 is in Phase II testing to treat various cancers. At least five companies have FGFR inhibitors in Phase II or earlier development to treat various cancers.

SciBX 6(31); doi:10.1038/scibx.2013.820
Published online Aug. 15, 2013

Unpatented; licensing not applicable

Ramsey, M.R. et al. J. Clin. Invest.; published online July 8, 2013;
Contact: Leif W. Ellisen, Massachusetts General Hospital Cancer Center, Boston, Mass.